Sublingual vs. Buccal Administration: Key Differences

Two Routes, One Medication

When a provider prescribes a ketamine troche, they may specify either sublingual or buccal administration — or leave it to patient preference. While both methods deliver the same medication through the oral mucosa — a process explained in detail in our article on troche absorption — there are meaningful differences in absorption rate, onset speed, intensity of initial effects, and patient comfort. Understanding these differences helps patients choose the approach that works best for their physiology and therapeutic goals.

Sublingual Administration: Under the Tongue

Sublingual means "under the tongue." To use this method, the patient places the troche beneath the tongue, where it rests against the sublingual mucosa — the thin, highly vascularized tissue lining the floor of the mouth.

Anatomy and Absorption

The sublingual mucosa is among the most permeable mucosal surfaces in the body. It is:

• Non-keratinized: Lacking the protective protein layer that slows drug penetration in other areas
• Thin: Approximately 100 to 200 micrometers, compared to 500 to 600 micrometers for buccal mucosa
• Highly vascularized: Dense capillary networks directly beneath the epithelium enable rapid drug uptake

The sublingual vein and lingual vein drain directly into the internal jugular vein, bypassing the portal system and first-pass hepatic metabolism. This direct drainage path means absorbed drug reaches systemic circulation quickly.

Onset and Intensity

Sublingual delivery typically produces a faster, more pronounced initial onset compared to buccal delivery at equivalent doses. Patients using the sublingual route often notice the first effects within 10 to 15 minutes of placement, with more rapid climb to peak than buccal administration.

For some patients, this faster onset is desirable — it signals quickly that absorption is occurring and allows the session to unfold on a predictable timeline. For others, particularly those anxious about the experience, a rapid climb to altered states can feel overwhelming in early sessions.

Practical Considerations for Sublingual Use

• The tongue naturally wants to move and manipulate objects placed under it; patients must practice conscious stillness.
• Saliva pools under the tongue; resist the urge to swallow frequently, as this removes drug-containing liquid before absorption is complete.
• Some patients find keeping the tongue pressed gently but firmly against the upper palate helps stabilize the troche and reduce saliva pooling.
• Discomfort from holding the troche in one position for 15 to 20 minutes is common initially but diminishes with practice.

Buccal Administration: Between Cheek and Gum

Buccal means "related to the cheek." In buccal administration, the troche is placed between the inner cheek and the upper or lower gum line, where it contacts the buccal mucosa.

Anatomy and Absorption

The buccal mucosa is:

• Partially keratinized: The outer layers provide more barrier resistance to drug penetration
• Thicker: Greater tissue depth means the drug must diffuse farther to reach capillaries
• Less densely vascularized in immediate surface layers compared to sublingual tissue

Because of these structural differences, buccal absorption is generally slower and produces a more gradual onset compared to sublingual administration.

Onset and Intensity

Buccal administration produces a slower, softer onset — typically 15 to 30 minutes before noticeable effects. The peak intensity may be slightly lower at equivalent doses, and the overall experience may feel more gradual. For patients who find rapid onset disorienting, buccal administration can make the first portion of a session feel more manageable.

Practical Considerations for Buccal Use

• Placement is easier to maintain than sublingual — the troche sits naturally in the buccal pouch without active tongue management.
• Saliva production is slightly less at the buccal site, which may reduce the amount of drug washed away from the absorption surface.
• Patients can alternate cheeks between sessions or if one side becomes irritated.
• Some patients find buccal administration causes less salivation than sublingual, making saliva management easier.

Comparing the Two Methods

Which Method Produces Higher Bioavailability?

Pharmacokinetic studies on sublingual versus buccal drug delivery generally show that sublingual administration produces slightly higher peak plasma concentrations (Cmax) and shorter time to peak (Tmax) for drugs with high sublingual permeability. However, total drug exposure over the full session (area under the curve, or AUC) may be comparable between the two routes because slower buccal absorption extends the duration of drug uptake.

For ketamine specifically, the clinical difference between the two routes may be modest in most patients. The most important variable is proper technique — a well-executed buccal administration outperforms a poorly executed sublingual one.

Patient Preference and Individual Response

Clinical experience from ketamine practitioners suggests that:

• Patients with anxiety about altered states often do better starting with buccal administration due to the gentler onset curve.
• Patients using troches for pain management often prefer sublingual administration because faster onset means faster pain relief.
• Patients who have difficulty keeping the tongue still (due to anxiety, movement disorders, or discomfort) often find buccal administration more comfortable.
• Patients who have experienced dry mouth from other medications may find sublingual administration challenging due to reduced saliva production.

There is no universally superior route. Many patients try both and settle on whichever feels most natural and produces the best therapeutic experience for them. For a step-by-step walkthrough of each approach, see our guides on sublingual technique and buccal technique. Discuss your experience with your provider — they may have specific recommendations based on your dose, goals, and reported response.

Combining or Alternating Routes

Some providers instruct patients to begin with buccal placement and transition to sublingual midway through the dissolution period, attempting to leverage the benefits of both. This is not standardized but has been used in clinical practice. If your provider specifies a particular approach, follow their instructions precisely rather than improvising.

Managing Oral Irritation

Both routes can occasionally cause mild mucosal irritation, particularly with repeated use at high doses. Signs of irritation include:

• Mild soreness or tenderness at the placement site
• Redness of the mucosa visible in a mirror
• Slight swelling of the gum or cheek tissue

To minimize irritation:

• Alternate the placement site between sessions when possible
• Ensure the troche is fully dissolved before removing any residue
• Rinse with water (not mouthwash containing alcohol) after sessions
• Report persistent or worsening irritation to your provider

Key Takeaways

• Sublingual administration (under the tongue) produces faster, more pronounced onset due to thinner, non-keratinized mucosa.
• Buccal administration (between cheek and gum) produces slower, more gradual onset — often preferred by anxious patients or those new to ketamine.
• Both routes deliver comparable total drug exposure when executed well.
• Patient preference and technique matter more than a theoretical "best" route.
• Discuss any differences in experience between the two methods with your prescriber.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches